Valuation: Gencurix Inc.

Market Cap 30.03B 22.1M 19.67M 18.38M 16.76M 31.44M 2.13B 31.89M 222M 86.04M 1.08B 83M 81.2M 3.5B P/E 2022
-1.86x
P/E 2023 -3.82x
Enterprise Value 35.66B 26.25M 23.36M 21.83M 19.9M 37.34M 2.53B 37.87M 264M 102M 1.29B 98.57M 96.44M 4.16B EV / Sales 2022
26.8x
EV / Sales 2023 34.6x
Free-Float
55.38%
Yield 2022 *
-
Yield 2023 -
1 day+0.88%
1 month-1.16%
3 months-11.25%
6 months-23.10%
Current year+26.18%
1 month 1,813
Extreme 1813
2,370
Current year 1,321
Extreme 1321
7,320
1 year 1,321
Extreme 1321
7,320
3 years 1,131
Extreme 1131
8,500
5 years 1,131
Extreme 1131
19,450
10 years 1,131
Extreme 1131
32,300
Manager TitleAgeSince
Chief Executive Officer 53 -
Chief Tech/Sci/R&D Officer 64 31/12/2014
Corporate Officer/Principal 61 30/03/2023
Director TitleAgeSince
Director/Board Member 53 -
Director/Board Member 61 30/03/2023
Director/Board Member 43 12/09/2023
Change 5-day change 1-year change 3-year change Capi.($)
+0.88%-.--%+11.70%-69.08% 33.85M
-2.17%-6.57%-27.81%-0.17% 171B
+0.17%-3.20%-9.24%+10.31% 110B
-0.88%-0.16%-26.16%-0.11% 106B
-0.69%-3.57%-47.61%-12.45% 75.99B
+3.17%-0.80%-0.88%+72.13% 57.3B
-0.52%-2.44%-4.86%-31.12% 48.76B
+3.44%+7.90%+19.12%+59.15% 50.19B
-0.85%-0.82%-18.96%+18.41% 41.14B
-0.07%-1.71%+28.15%-7.58% 32.56B
Average +0.20%-0.79%-7.66%+3.95% 69.3B
Weighted average by Cap. -0.38%-2.07%-16.38%+9.01%

Financials

2022 2023
Net sales 2.56B 1.88M 1.68M 1.57M 1.43M 2.68M 181M 2.72M 18.93M 7.33M 92.45M 7.07M 6.92M 299M 2.6B 1.91M 1.7M 1.59M 1.45M 2.72M 184M 2.76M 19.23M 7.45M 93.93M 7.19M 7.03M 303M
Net income -24.6B -18.1M -16.11M -15.05M -13.73M -25.75M -1.74B -26.12M -182M -70.47M -888M -67.99M -66.51M -2.87B -19.26B -14.18M -12.62M -11.79M -10.75M -20.17M -1.37B -20.45M -142M -55.18M -696M -53.23M -52.08M -2.25B
Net Debt 22.55B 16.6M 14.77M 13.8M 12.58M 23.61M 1.6B 23.95M 167M 64.6M 815M 62.33M 60.97M 2.63B 5.63B 4.15M 3.69M 3.45M 3.14M 5.9M 399M 5.98M 41.66M 16.14M 203M 15.57M 15.23M 657M
Logo Gencurix Inc.
Gencurix Inc. is a Korea-based company mainly engaged in the sale of medical equipments. In addition, the Company is involved in the manufacturing and sale of breast cancer test (BCT) kits, Korean genetic polymorphism diagnostic kits, lung cancer and colorectal cancer diagnostic kits. The BCT kits are used for analyzing the expression level of the cancer-related gene. The products are sold under the name of GenesWell.
Employees
-
  1. Stock Market
  2. Stocks
  3. A229000 Stock